(Q38893104)

7 September 2017

1 reference

title

Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time (English)

1 reference

7 September 2017

5

1 reference

Francesca Ceccherini-Silberstein

7 September 2017

2

object named as

Francesca Ceccherini-Silberstein

1 reference

7 September 2017

3

Kristel Van Laethem

0 references

Lize Cuypers

object named as

Lize Cuypers

1

0 references

author name string

Guangdi Li

4

1 reference

7 September 2017

Jürgen Kurt Rockstroh

6

1 reference

7 September 2017

publication date

12 July 2016

1 reference

Reviews in Medical Virology

7 September 2017

published in

1 reference

7 September 2017

volume

26

1 reference

7 September 2017

issue

6

1 reference

7 September 2017

page(s)

408-434

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

7 September 2017

cites work

1 reference

The global burden of disease attributable to contaminated injections given in health care settings

21 January 2018

1 reference

Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource

21 January 2018

1 reference

Phylogeny and molecular evolution of the hepatitis C virus

21 January 2018

1 reference

Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance

21 January 2018

1 reference

Global distribution and prevalence of hepatitis C virus genotypes

21 January 2018

1 reference

Epidemiology and natural history of HCV infection.

21 January 2018

1 reference

Global epidemiology and genotype distribution of the hepatitis C virus infection

21 January 2018

1 reference

The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.

21 January 2018

1 reference

Epidemiology of viral hepatitis and HIV co-infection

21 January 2018

1 reference

Viral hepatitis and HIV co-infection

21 January 2018

1 reference

The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection

21 January 2018

1 reference

Predictors of Mortality among United States Veterans with Human Immunodeficiency Virus and Hepatitis C Virus Coinfection

21 January 2018

1 reference

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

21 January 2018

1 reference

A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

21 January 2018

1 reference

HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma.

21 January 2018

1 reference

Hepatitis C treatment: current and future perspectives

21 January 2018

1 reference

Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy

21 January 2018

1 reference

Directly acting antivirals against hepatitis C virus

21 January 2018

1 reference

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials

21 January 2018

1 reference

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

21 January 2018

1 reference

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial

21 January 2018

1 reference

Hepatitis C therapy with HCV NS5B polymerase inhibitors

21 January 2018

1 reference

Hepatitis C virus protease inhibitor-resistance mutations: our experience and review

21 January 2018

1 reference

Hepatitis C virus NS5A inhibitors and drug resistance mutations

21 January 2018

1 reference

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

21 January 2018

1 reference

The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis

21 January 2018

1 reference

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

21 January 2018

1 reference

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

21 January 2018

1 reference

Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late

21 January 2018

1 reference

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

21 January 2018

1 reference

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

21 January 2018

1 reference

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

21 January 2018

1 reference

No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL

21 January 2018

1 reference

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

21 January 2018

1 reference

How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?

21 January 2018

1 reference

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

21 January 2018

1 reference

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

21 January 2018

1 reference

ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.

21 January 2018

1 reference

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial

21 January 2018

1 reference

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

21 January 2018

1 reference

Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders

21 January 2018

1 reference

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

21 January 2018

1 reference

Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders

21 January 2018

1 reference

High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study

21 January 2018

1 reference

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

21 January 2018

1 reference

Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent

21 January 2018

1 reference

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a

21 January 2018

1 reference

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.

21 January 2018

1 reference

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

21 January 2018

1 reference

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

21 January 2018

1 reference

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

21 January 2018

1 reference

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

21 January 2018

1 reference

Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.

21 January 2018

1 reference

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection

21 January 2018

1 reference

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study

21 January 2018

1 reference

Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A.

21 January 2018

1 reference

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

21 January 2018

1 reference

Is genotype 3 of the hepatitis C virus the new villain?

21 January 2018

1 reference

Antiviral activity and resistance of HCV NS5A replication complex inhibitors

21 January 2018

1 reference

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

21 January 2018

1 reference

Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV.

21 January 2018

1 reference

Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry

21 January 2018

1 reference

Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4.

21 January 2018

1 reference

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

21 January 2018

1 reference

New hepatitis C therapies: the toolbox, strategies, and challenges

21 January 2018

1 reference

Nucleotide polymorphisms in the 5'-UTR region of HCV can affect the ability of two widely used assays to assign an HCV genotype

21 January 2018

1 reference

Hepatitis C virus genotyping: interrogation of the 5' untranslated region cannot accurately distinguish genotypes 1a and 1b

21 January 2018

1 reference

Improvement of Hepatitis C Virus (HCV) Genotype Determination with the New Version of the INNO-LiPA HCV Assay

21 January 2018

1 reference

The need for a sequencing-based assay to supplement the Abbott m2000 RealTime HCV Genotype II assay: a 1 year analysis

21 January 2018

1 reference

Evaluation of sequencing of HCV core/E1, NS5A and NS5B as a genotype predictive tool in comparison with commercial assays targeting 5'UTR.

21 January 2018

1 reference

Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents

21 January 2018

1 reference

Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy

21 January 2018

1 reference

Hepatitis C virus mixed genotype infection in patients on haemodialysis

21 January 2018

1 reference

Evaluation of three different hepatitis C virus typing methods for detection of mixed-genotype infections.

21 January 2018

1 reference

Mixed genotype hepatitis C infections and implications for treatment.

21 January 2018

1 reference

Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis

21 January 2018

1 reference

Antiviral therapy of hepatitis C in 2014: do we need resistance testing?

21 January 2018

1 reference

Rapid emergence of protease inhibitor resistance in hepatitis C virus

21 January 2018

1 reference

Hepatitis C virus drug resistance-associated substitutions: State of the art summary

21 January 2018

1 reference

Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir

21 January 2018

1 reference

Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data

21 January 2018

1 reference

The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors

21 January 2018

1 reference

Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies

21 January 2018

1 reference

In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

21 January 2018

1 reference

Treatment of HCV infection with the novel NS3/4A protease inhibitors.

21 January 2018

1 reference

The importance of resistance to direct antiviral drugs in HCV infection in clinical practice

21 January 2018

1 reference

Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.

21 January 2018

1 reference

Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.

21 January 2018

1 reference

Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition

21 January 2018

1 reference

Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052

21 January 2018

1 reference

Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.

21 January 2018

1 reference

In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.

21 January 2018

1 reference

Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir

21 January 2018

1 reference

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

21 January 2018

1 reference

Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.

21 January 2018

1 reference

Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir

21 January 2018

1 reference

Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection

21 January 2018

1 reference

Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region

21 January 2018

1 reference

Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients

21 January 2018

1 reference

L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.

21 January 2018

1 reference

Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C.

21 January 2018

1 reference

Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.

21 January 2018

1 reference

Virologic Tools for HCV Drug Resistance Testing

21 January 2018

1 reference

Deep sequencing: becoming a critical tool in clinical virology

21 January 2018

1 reference

Detection of a sexually transmitted hepatitis C virus protease inhibitor-resistance variant in a human immunodeficiency virus-infected homosexual man.

21 January 2018

1 reference

Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM.

21 January 2018

1 reference

High incidence of hepatitis C virus reinfection within a cohort of injecting drug users

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/RMV.1895

1 reference

7 September 2017

1 reference